'I'm still here:' South Florida patients see early promising results from new pancreatic cancer pill

Daraxonrasib, an FDA-approved drug targeting a common mutation in pancreatic cancer, has shown promising early results by nearly doubling median survival time for late-stage patients and is becoming available through expanded access programs and insurance coverage.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.